Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

KALA BIO Inc

KALA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.18

▲ +13.73%

Market Cap $3.43M · Vol 15.66K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.43M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

44.13

Momentum

Beta

-2.22

vs Market

52W High

$95.50

99.81% below

52W Low

$0.12

47.50% above

Volume

15.66K

Avg 143.40K

P/B

2.21

Price-to-book

ROE

N/A

Return on equity

Free Float

93.76%

Public shares

Shariah Compliance8 STANDARDS

✗ KALA BIO Inc (KALA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KALA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.42%

-39.69%

-76.29%

-95.53%

YTD

-99.36%

-99.50%

-99.94%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,980,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-83.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.21
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	19.34M

Technical Indicators

50-Day SMA	$0.37
200-Day SMA	$5.89
RSI (14)	44.13
Beta	-2.22
52-Week High	$95.50
52-Week Low	$0.12

Volume Today	15.66K
Avg Daily Volume (30D)	143.40K
Relative Volume	0.11x
Volatility (10D)	111.81
Volatility (30D)	137.06
Free Float	93.76%

Analyst Consensus

N/A

Current Price $0.18

Mean Target N/A

52W Low$0.12 52W High$95.50

Current

Target

$0.12 $95.50

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001V0GBM6

ISINUS4831193010

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.27% ARGX.BR argenx SE +4.66% ARGX argenx SE +3.78% GMAB.CO Genmab A/S +3.80% GMAB Genmab A/S +4.05%

Company Profile

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.